Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
View Older Stories
-
TD Cowen Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
-
Ionis Pharmaceuticals (IONS) PT Raised to $59 at TD Cowen
-
TD Cowen Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
-
Ionis to present at TD Cowen Genetic Medicines & RNA Summit
-
TD Cowen Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
-
Ionis to present at upcoming investor conferences
-
Ionis to present at upcoming investor conference
-
Ionis to present at upcoming investor conferences
-
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
-
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
-
Ionis Pharmaceuticals (IONS), Royalty Pharma (RPRX) enter into royalty agreement for up to $1.1 billion
-
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness
-
Ionis to present at the Cowen Annual Health Care Conference
-
Cowen Upgrades Ionis Pharmaceuticals (IONS) to Outperform
-
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
-
Ionis Pharmaceuticals (IONS) to acquire remaining stake in Akcea Therapeutics (AKCA) for $18.15/sh
-
Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
-
Ionis Pharmaceuticals to present at upcoming investor conferences
-
Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference
-
Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference
-
Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
-
Ionis Pharmaceuticals (IONS) Announces Dr. Michael Hayden & Peter N. Reikes to Board
-
Ionis Announces the Appointment of Two New Board Members
-
Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTR
-
Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTR
-
Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTR
-
Ionis Pharma (IONS), Akcea Therapeutics (AKCA) Partner on Inotersen for hATTR; $150M Upfront to Ionis Paid in Stock
-
Ionis and Akcea Partner to Commercialize Inotersen for hATTR
-
Akcea Therapeutics to Present at Upcoming Investor Conferences
-
Akcea Therapeutics to Present at Upcoming Investor Conferences
-
Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
-
Akcea Therapeutics (AKCA) Closes IPO, Reports $50M Private Placement with Novartis Pharma (NVS)
-
Akcea Therapeutics Announces Closing of Initial Public Offering
-
Akcea Therapeutics Announces Pricing of Initial Public Offering
-
Akcea Therapeutics (AKCA) Launches Proposed IPO with Initial Offering Price of $12 to $14/Share (IONS)
-
Akcea Therapeutics Launches Proposed Initial Public Offering
-
Cowen Reiterates Outperform Rating and $100 PT on Alnylam Pharma (ALNY); 'Ionis Pharma (IONS) Data Show Efficacy in FAP Bodes Well for Ph3 APOLLO in Sept.'
-
Ionis Pharma (IONS) Spinoff Akcea Therapeutics (AKCA) Files IPO
-
Akcea Therapeutics Files Registration Statement for Proposed Initial Public Offering
-
Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
-
Notable Analyst Rating Changes 8/3: (ZNGA) (NMBL) (AVD) Upgraded; (CSIQ) (EQR) (EMR) Downgraded
-
Cowen Downgrades Ionis Pharmaceuticals (IONS) to Market Perform
-
Akcea Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference
-
Trading Radar for 2/25: Baidu (BIDU), Best Buy (BBY), Sears (SHLD), Weight Watchers (WTW) Report
-
Ionis Pharmaceuticals to Present at Upcoming Investor Conferences

